Abstract
Clinical pharmacology profile of an oral selective androgen receptor down-regulator, AZD3514: Implications on the design of ongoing castrate-resistant prostate cancer clinical studies
Highlights
Prostate cancer is a common disease and is most often effectively treated with surgery or radiotherapy
Evidence has accumulated that tumor growth in castrate-resistant prostate cancer (CRPC) is still dependent on the androgen receptor (AR) and the AR has become a target for drug development with abiraterone and enzalutamide recently reaching the market [3,4,5,6]
At steady state on Day 29 and following once daily (QD) dosing, values for Cssmax and tssmax were generally similar to those observed after single-dose administration and there was no evidence of accumulation (Tables 1 and 2)
Summary
Prostate cancer is a common disease and is most often effectively treated with surgery or radiotherapy. In patients with aggressive forms or metastatic disease, treatment is more difficult. In such patients, the standard of care is androgen deprivation therapy achieved by either surgical castration or administration of luteinizing hormone-releasing hormone agonists [1, 2]. Evidence has accumulated that tumor growth in castrate-resistant prostate cancer (CRPC) is still dependent on the androgen receptor (AR) and the AR has become a target for drug development with abiraterone and enzalutamide recently reaching the market [3,4,5,6]. Despite castrate levels of testosterone in CRPC patients, resistance develops, which in many cases is still dependent on AR [7,8,9,10], and new drugs that are less prone to, or can over-come, the development of resistance are needed
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
